StockNews.AI
VTVT
StockNews.AI
19 hrs

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

1. vTv Therapeutics participates in September investor conferences to discuss their drug. 2. Cadisegliatin is in Phase 3 trials for type 1 diabetes treatment. 3. Management aims to attract investor interest in their novel therapies. 4. Conferences include H.C. Wainwright and Morgan Stanley healthcare events. 5. The company's focus remains on diabetes and chronic disease treatments.

6m saved
Insight
Article

FAQ

Why Bullish?

Participation in investor conferences often leads to positive sentiment; similar firms see gains post-event.

How important is it?

Investor participation indicates active engagement, likely fostering positive outlook and investment.

Why Short Term?

Investor conferences can yield immediate interest, similar to past presentations by biotech firms like Moderna.

Related Companies

HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences:

H.C. Wainwright 27th Annual Global Investment Conference

Date:Tuesday, September 9, 2025
Format:1x1 Investor Meetings Only
  
Morgan Stanley 23rd Annual Global Healthcare Conference 
Date:Wednesday, September 10, 2025
Format:Fireside Chat Time: 2:35 PM - 3:10 PM EST and 1x1 Investor Meetings
  

About vTv Therapeutics

vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.

Investor Contact

John Fraunces

LifeSci Advisors, LLC

jfraunces@lifesciadvisors.com

Media Contact

Caren Begun

TellMed Strategies

201-396-8551

caren.begun@tmstrat.com



Primary Logo

Related News